Endoplasmic reticulum (ER) stress has been implicated in the development of maternal diabetes-induced neural tube defects (NTDs). ER stress-induced C/EBP homologous protein (CHOP) plays an important role in the pro-apoptotic execution pathways. However, the molecular mechanism underlying ER stress-and CHOP-induced neuroepithelium cell apoptosis in diabetic embryopathy is still unclear. Deletion of the Chop gene significantly reduced maternal diabetes-induced NTDs. CHOP deficiency abrogated maternal diabetes-induced mitochondrial dysfunction and neuroepithelium cell apoptosis. Further analysis demonstrated that CHOP repressed the expression of peroxisome-proliferator-activated receptor-c coactivator-1a (PGC-1a), an essential regulator for mitochondrial biogenesis and function. Both CHOP deficiency in vivo and knockdown in vitro restore high glucose-suppressed PGC-1a expression. In contrast, CHOP overexpression mimicked inhibition of PGC-1a by high glucose. In response to the ER stress inducer tunicamycin, PGC-1a expression was decreased, whereas the ER stress inhibitor 4-phenylbutyric acid blocked high glucose-suppressed PGC-1a expression. Moreover, maternal diabetes in vivo and high glucose in vitro promoted the interaction between CHOP and the PGC-1a transcriptional regulator CCAAT/enhancer binding protein-b (C/EBPb), and reduced C/EBPb binding to the PGC-1a promoter leading to markedly decrease in PGC-1a expression. Together, our findings support the hypothesis that maternal diabetes-induced ER stress increases CHOP expression which represses PGC-1a through suppressing the C/EBPb transcriptional activity, subsequently induces mitochondrial dysfunction and ultimately results in NTDs.
downstream of ER stress that mediate the teratogenicity of maternal diabetes remain to be elucidated.
CCAAT/enhancer-binding proteins (C/EBPs), a family of transcription factors, regulate an array of cellular functions including cell differentiation and apoptosis (Ramji and Foka, 2002) . There are 6 members in the C/EBPs family including C/EBPa, b, c, d, e, and C/EBP homologous protein (CHOP), which is also known as growth arrest and DNA damage-inducible gene 153 (GADD153) (Ramji and Foka, 2002) . CHOP has been defined as an ER chaperone gene that mediates the pro-apoptotic effect of prolonged ER stress (Iurlaro and Munoz-Pinedo, 2016; Sano and Reed, 2013) . Several pro-apoptotic events downstream of CHOP have been identified. CHOP modulates the Bcl-2 family members by down-regulating the anti-apoptotic Bcl-2 family proteins such as Mcl-1 and Bcl-2, and up-regulating the proapoptotic protein Bim (Iurlaro and Munoz-Pinedo, 2016) . CHOP activates the death receptor 5 (DR5) which induces apoptosis through caspase 8 activation (Iurlaro and Munoz-Pinedo, 2016) . CHOP is expressed in a low level under non-stress conditions, whereas its expression is robustly increased by the 3 arms of the unfolded protein response (UPR): IRE1a, PERK, and ATF6a, upon ER stress (Senft and Ronai, 2015) . It has been shown that maternal diabetes induces ER stress and UPR activation leading to a robust increase of apoptosis in the developing neuroepithelium (Dong et al., 2016a; Gu et al., 2016; Li et al., 2013) . However, the role CHOP in diabetic embryopathy is still elusive.
Consistent with the adverse impact of CHOP on Bcl-2 family members, critical regulators of mitochondrial function, defective mitochondrial, and mitochondrial dysfunction are manifested in neuroepithelial cells exposed to maternal diabetes (Wang et al., 2017; Xu et al., 2013) , suggesting that CHOP may alter mitochondrial function by modulating key mitochondrial regulators.
Peroxisome-proliferator-activated receptor-c coactivator-1 alpha (PGC-1a) is a master regulator of mitochondrial biogenesis (Austin and St-Pierre, 2012; Scarpulla, 2011) , and its activity is regulated by transcriptional and post-transcriptional mechanisms (Karamanlidis et al., 2007; Karamitri et al., 2009; Wang et al., 2008 Wang et al., , 2017 . Maternal diabetes suppresses PGC-1a expression (Wang et al., 2017) . Previous studies have demonstrated that C/EBPb is a positive transcriptional regulator for PGC-1a in the liver (Wang et al., 2008) . C/EBPb-induced PGC-1a expression is hindered by a transcription repressor, histone deacetylase 1 (Jin et al., 2013) . Because CHOP represses gene transcription through binding with other C/EBP proteins and, thus, preventing them binding to DNA (Ron and Habener, 1992) , CHOP may participate in maternal diabetes-repressed PGC-1a expression by interfering with the DNA binding activity of other C/EBP proteins. In addition, CHOP suppresses metabolic gene expression during ER stress in the liver (Chikka et al., 2013) . Thus, CHOP may contribute to ER stress-induced neuroepithelial cell apoptosis and NTD formation through suppression of PGC-1a expression in diabetic embryopathy.
In the present study, we report that ER stress-increased CHOP is responsible for maternal diabetes-induced neuroepithelial cell apoptosis and NTD formation using CHOP knockout mice. We further reveal that deletion of the Chop gene reverses maternal diabetes-induced mitochondrial dysfunction and restores PGC-1a expression. C/EBPb is a transcriptional activator for PGC-1a in the developing embryo, whereas CHOP blocks the DNA-binding ability of C/EBPb through forming CHOP/C/EBP heterodimer and represses PGC-1a expression. These findings support the important role of CHOP-suppressed PGC-1a in ER stress-induced diabetic embryopathy.
MATERIALS AND METHODS
Mice. All procedures for animal use were approved by the Institutional Animal Care and Use Committee of University of Maryland School of Medicine. Wild-type (WT) C57BL/6J mice and CHOP knockout mice were purchased from the Jackson Laboratory (Bar Harbor, ME). The male CHOP þ/À mice was mated with non-diabetic or diabetic female CHOP þ/À to generate WT,
Model of diabetic embryopathy and morphological assessment of NTDs. We (Gu et al., 2016; Li, et al., 2012 Li, et al., , 2013 Wang et al., 2015b; Yang et al., 2013; Zhong et al., 2016a) and others (Kamimoto et al., 2010; Salbaum and Kappen, 2010; Sugimura et al., 2009) Hematoxylin-eosin staining. E10.5 embryos were fixed in methacarn (60% methanol, 30% chloroform, and 10% glacial acetic acid), embedded in paraffin, and cut into 5 lm sections. After deparaffinization and rehydration, all specimens then underwent hematoxylin and eosin (H & E) staining in a standard procedure. All sections were photographed and examined for neural tube defects.
TUNEL staining. The TUNEL assay was performed using the In Situ Cell Death Detection Kit (Millipore) as previously described (Gu et al., 2016; Yang et al., 2013 Cell culture and treatment. C17.2 mouse neural stem cells, originally obtained from ECACC (European Collection of Cell Culture), were maintained in DMEM (5 mM glucose) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin at 37 C in a humidified atmosphere of 5% CO 2 . The C17.2 cells are newborn mouse cerebellar progenitor cells transformed with retroviral v-myc (Snyder et al., 1992) . Lipofectamine 2000 (Invitrogen) was used according to the manufacturer's protocol for transfection of CHOP siRNA or scramble control siRNA (Thermo Scientific) and C/EBPb expression vector into the cells using 1% fetal bovine serum culture conditions. C/EBPb expression vector was a gift from Jed Friedman (addgene # #49198). In order to investigate the possible effect of ER stress on PGC-1a expression, ER stress inducer tunicamycin (1 lg/ml) (Sigma-Aldrich) was added to growth medium for indicated time in figures and then cells were harvested. To determine the effect of the ER stress inhibitor 4-phenylbutyric acid (4-PBA) on tunicamcin-suppressed PGC-1a expression, cells were cultured in tunicamycin for 6 h and then treated with 4-PBA (2 mmol/L) for another 48 h.
Immunoblotting. To extract protein, the embryos or cells were sonicated in ice-cold lysis buffer (Cell Signaling Technology, Beverly, MA) with protease inhibitor cocktail (Sigma-Aldrich). The mitochondria were isolated from the embryos using the Pierce mitochondria isolation kit. Equal amounts of protein from different experimental groups were resolved by the SDS-PAGE gel electrophoresis and transferred onto Immunobilon-P membranes (Millipore). Membranes were incubated in 5% nonfat milk for 45 min and then were incubated for 18 h at 4 C with the following primary antibodies in 5% non-fat milk: protein Bcl-2 homologous antagonist killer (Bak) (Cell Signaling Technologies, dilution 1:1000), Bax (Cell Signaling Technologies, dilution 1:1000), p53 upregulated modulator of apoptosis (Puma) (Cell Signaling Technologies, dilution 1:1000), Bim (Cell Signaling Technologies, dilution 1:1000), tBid (Cell Signaling Technologies, dilution 1:1000), phosphorylated Bcl-2-associated death promoter (pBad), caspase 3 (Millipore, dilution 1:1000), caspase 8 (Enzo Technologies, dilution 1:1000), CHOP (Cell Signaling Technologies, dilution 1:1000), PGC-1a (Santa Cruz, dilution 1:1000), and C/EBPb (Cell Signaling Technologies, dilution 1:1000). Membranes were then exposed to goat anti-rabbit or anti-mouse secondary antibodies (KPL, dilution 1:10000). To confirm that equivalent amounts of protein were loaded among samples, membranes were stripped and probed with a mouse antibody against b-actin (Abcam, dilution 1:5000). Signals were detected using the SuperSignal West Femto Maximum Sensitivity Substrate kit (Thermo Scientific). All experiments were repeated 3 times with the use of independently prepared tissue or cell lysates.
Electron microscopy. Mitochondrial structures were examined by transmission electron microscopy (EM) in our university's EM core facility. Thick sections (1 lm) were cut and visualized at 100 Â magnification to identify the neuroepithelia of the E8.75 embryos. Thin sections (80 nm) of identified neuroepithelia were cut and viewed with an electron microscope (Joel JEM-1200EX; Tokyo, Japan) at high resolution (10, 12, and 25 K) to identify the cellular organelle structures.
Neural stem cell isolation and flow cytometry analysis of mitochondrial potential. E8.75 embryos were dissected out of the uterus and then yolk sacs were removed from the embryos. The whole embryos were digested by Dispase II (3 mg/ml in PBS pH ¼ 7.4) for 15 min at room temperature in order to remove non-neural tissue (De Bellard et al., 2002; Etchevers, 2011) . After digestion of Dispase II, the whole neural tubes were washed with PBS for 3 times, cut into pieces and digested with 0.25% trypsin-EDTA (Thermo Scientific) for 5 min at 37 C with shaking. The cell suspensions were centrifuged at 500 Â g for 5 min and resuspended in DMEM medium (Thermo Scientific) with 10%FBS (Thermo Scientific) following by filtration using 70 lm cell strainer. The isolated cells were seeded into 6-well plate. The mitochondrial potential was analyzed using JC-1 dye (Invitrogen). Briefly, after adhesion, the isolated neural stem cells were incubated with JC-1 dye-contained culture medium (1 mg/ml) for 15 min at 37 C.
After dye staining, the cells were harvested and washed with PBS for 3 times. The stained cells were analyzed by a flow cytometer.
PGC-1a promoter activity analysis. The PGC-1a promoter containing the transcription factor C/EBPb binding site was subcloned and inserted into the pGL4.10 Luciferase Reporter Vectors (Promega). Transfection of pGL4.1-PGC-1a promoter vector into mouse neural stem cell line C17.2 was performed using Lipofectamine 2000 (Invitrogen) and then the cells were cultured for 48 h with or without high glucose (25 mM) combined with CHOP siRNA transfection or 6 h with or without tunicamycin (1 lg/ml) combined with 4-PBA (2 mM) for another 48 h. Cells were harvested and lysated using lysis buffer from the Dual luciferase Assay system (promega). The firefly luciferase activities were measured using the Dual luciferase Assay system (promega). The firefly luciferase activities were normalized to internal control Renilla luciferase.
Immunoprecipitation. Cells were lysed in the non-denaturing lysis buffer containing 20 mM of Tris-HCl (pH 7.5), 150 mM of NaCl, 1 mM of Na 2 EDTA, 1 mM of EGTA, 1% Triton, 2.5 mM of sodium pyrophosphate, 1 mM of bÀglycerophosphate, 1 mM of Na 3 VO 4 , and 1 lg/ml of leupeptin (Cell Signaling technology). Protease inhibitor (Sigma) was added before use. After centrifugation at 12 000 Â g for 10 min at 4 C, the supernatant was pre-cleaned with protein A/G magnetic beads (Thermo Scientific) for 2 h at 4 C. About 300 lg of protein extraction were incubated with an anti-CHOP primary antibody (Cell Signaling Technologies) at 4 C overnight. Twenty-five microliters of protein A/G magnetic beads was added for immunoprecipitation at room temperature for 2 h. Precipitated complexes were cleansed in washing buffer (Thermo Scientific), and bound proteins were analyzed by immunoblotting.
Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) assay was assessed by the Magna CHIP TM and EZ-Magna CHIP TM kits (Millipore). In brief, fresh cells and embryos were crosslinked in 1% formaldehyde at room temperature for 10 min and then stopped by 1Â Glycine. Cells and embryos were lysed by sonication to shear DNA on wet ice. Lysates were spun at 10 000 Â g for 10 min at 4 C to remove insoluble material.
Each 25-mg DNA chromatin sample was adjusted to a total volume of 500 ml in 450 ml of the Dilution Buffer containing protease inhibitors. Chromatin samples were then incubated with anti-C/EBPb (HÀ7) X (Santa Cruz, CA) or anti-rabbit IgG antibody (Cell Signaling Technologies) and fully suspended in protein A/G magnetic beads overnight at 4 C with gentle rotation. Magnetic beads were washed and immunoprecipitated DNAs were eluted with 100 ml CHIP Elution Buffer with Proteinase K at 62 C for 2 h.
DNAs were purified using the Spin Columns and DNAs were dissolved in the Elution Buffer C. Chromatin DNAs were analyzed by PCR and Real-time Quantitative PCR (qPCR) as previously described (Wang et al., 2008) . Primers used for CHIP PCR and qPCR were as follows (designated from 5 0 to 3 0 ): position À2409
to À2398 forward-GGGGAACCCAAGAGTCT and reverse-CCC AAATCAGCTGTCTCCT; position À765 to À754 forward-GGGC TGCCTTGGAGTGACG and reverse-GTCCCCAGTCACATGACAAA; position À16 to À5 forward-CTGAGTCTGGGGCTACTTGG and reverse-TCCATCCAAAACAGGCAAAT.
Statistical analyses. All experiments were completely randomized designed and repeated in triplicate. Data are presented as means 6 standard errors (SE). Student's t-test was used for 2 group comparisons. One-way or two-way ANOVA was performed for more than 2 group comparisons using the SigmaStat 3.5 software. In ANOVA analysis, a Tukey test was used to estimate the significance. Significant differences between groups in NTD incidence expressed by number of embryos were analyzed by v2 test or Fisher's exact test using SigmaStat 3.5 software. Statistical significance was indicated when p < .05.
RESULTS

Chop Gene Deletion Ameliorates Apoptosis and NTDs in Diabetic Embryopathy
In the diabetic embryopathy model, the average blood glucose level was significantly higher in the diabetic group than that in the non-diabetic group ( Figure 1A and Table 1 ). Maternal diabetes increased CHOP expression at the mRNA and protein levels, whereas Chop gene deletion completely abolished CHOP expression in the developing embryo ( Figure 1B and C). To investigate the effect of Chop gene deletion on maternal diabetes-induced NTDs, a total of 157 embryos from 23 dams including 9 non-diabetic dams and 14 diabetic dams were harvested and examined for failed neural tube closure (Table 1) . Under non-diabetic conditions, Chop gene deletion did not affect embryonic neurulation (Table 1 and Figure 1D and E). Under diabetic conditions, maternal diabetes significantly increased the NTD incidence to 32.0% in WT embryos (Table 1 and Figure 1D and E). However, Chop gene deletion significantly alleviated NTD formation with a NTD incidence of 7.7% in embryos from diabetic dams (Table 1 and Figure 1D and E). Heterozygous Chop deletion did not significantly reduced NTD incidence induced by maternal diabetes (Table 1 and Figure 1D and E). Neuroepithelial cell apoptosis is a causal factor for maternal diabetes-induced NTDs (Dong et al., 2016a, b; Gu et al., 2015 Gu et al., , 2016 Li et al., 2012 Li et al., , 2013 Yang et al., 2013 Yang et al., , 2015 . Chop gene deletion significantly reduced the number of apoptotic cells in the developing neuroepithelium compared to that in the neuroepithelium of WT embryos under diabetic conditions ( Figure 1F ). Maternal diabetes triggered caspase 3 and caspase 8 cleavage in WT embryos, whereas Chop gene deletion abrogated maternal diabetes-induced caspase 3 and caspase 8 cleavage in neurulation stage embryos ( Figure 1G and H) . The findings collectively demonstrate that Chop gene deletion ameliorates diabetic embryopathy by suppressing neuroepithelial cell apoptosis.
Chop Gene Deletion Preserves Mitochondrial Function in Diabetic Embryopathy
Previous studies have shown that maternal diabetes causes mitochondrial defects such as disarrayed or disruptive cristae and decreased electronic density of the matrix (Wang et al., 2017; Xu et al., 2013) . Indeed, maternal diabetes significantly increased the number of defective mitochondria in neuroepithelial cells of WT embryos (Figure 2A) . Chop gene deletion significantly reduced the number of defective mitochondria in neuroepithelial cells of embryos exposed to diabetes comparable to that in the non-diabetic group (Figure 2A) . The mitochondrial membrane potential as an indicator of mitochondrial function was assessed by the JC-1 dye staining. Maternal diabetes triggers mitochondrial depolarization indicated by the increase of the green/red fluorescence intensity ratio ( Figure  2B ). Chop gene deletion abolished maternal diabetes-induced mitochondrial depolarization ( Figure 2B ).
Furthermore, Chop gene deletion suppressed maternal diabetes-induced mitochondrial translocation of several proapoptotic Bcl-2 members including Bax, Puma, Bak, and Bim ( Figure 2C ). The active form of Bid, cleaved Bid, was significantly increased, whereas the inactive form of Bad, phosphorylated Bad, was significantly decreased in embryos from diabetic dams compared to those in embryos from non-diabetic dams ( Figure  2D ). Chop gene deletion reversed maternal diabetes-induced Bid cleavage and Bad dephosphorylation in the developing embryo ( Figure 2D ). These findings support the hypothesis that Chop gene deletion restores mitochondrial function in embryos exposed to maternal diabetes.
High Glucose Inhibits PGC-1a Expression Through CHOP PGC-1a is a master regulator of mitochondrial biogenesis and respiration (Austin and St-Pierre, 2012; Scarpulla, 2011) . Tissue from Ppargc1a-null mice display reduced expression of mitochondrial genes, decreased mitochondrial respiration and impaired mitochondrial function (Arany et al., 2005; Lin et al., 2004) . Maternal diabetes suppressed PGC-1a expression, whereas Chop gene deletion restored PGC-1a expression in embryos exposed to maternal diabetes ( Figure 3A ). High glucose (25 mM) in vitro significantly increased CHOP expression ( Figure 3B ) and decreased PGC-1a expression ( Figure 3C ) compared to the normal glucose group (5 mM). CHOP siRNA knockdown repressed high glucose-increased CHOP expression ( Figure 3B and D) and abrogated high glucoseinhibited PGC-1a expression ( Figure 3C and D) , indicating maternal diabetes in vivo-or high glucose in vitro-increased CHOP inhibits PGC-1a expression. CHOP overexpression mimicked high glucose in suppressing PGC-1a expression at both mRNA and protein levels ( Figure 3E and F) .
High glucose significantly decreased PGC-1a promoter activity and CHOP siRNA knockdown restored PGC-1a promoter activity ( Figure 3G ). CHOP overexpression mimicked the inhibitory effect of high glucose on PGC-1a promoter activity ( Figure 3G ). Thus, maternal diabetes in vivo or high glucose in vitro inhibits PGC-1a expression through CHOP at the transcriptional level.
The ER Stress Inducer Tunicamycin Represses PGC-1a Through CHOP To further elucidate the effect of CHOP on PGC-1a expression, the ER stress inducer tunicamycin was used to increase CHOP expression (Wang et al., 2015b) . Tunicamycin robustly increased CHOP expression along with the decrease of PGC-1a mRNA and protein expression in a dose-dependent manner ( Figure 4A and B) . Experiments were repeated using 3 embryos (N¼3) from different dams and 3 images were obtained from each embryo. Scale bars: 70 mm. The protein abundance of cleaved caspase 3 (G) and caspase 8 (H) in E8.5 embryos. Bar graphs for protein abundance were quantitative data from 3 independent experiments. ND: non-diabetic dams; DM: diabetic dams; NTD: neural tube defect; KO: CHOP knockout. * indicate significant difference (p < .05) compared with other groups. The ER stress inhibitor 4-PBA blocked high glucose-increased CHOP expression and reversed high glucose-suppressed PGC-1a expression ( Figure 4B ). Tunicamycin repressed PGC-1a promoter activity and 4-PBA abolished high glucose-suppressed PGC-1a promoter activity ( Figure 4C ). These data indicate that ER stressinduced CHOP negatively regulates PGC-1a expression.
C/EBPb Abolishes High Glucose-and Tunicamycin-Suppressed PGC-1a Expression
It has been shown that CCAAT/enhancer binding protein beta (C/EBPb) is a transcriptional regulator of PGC-1a expression in adipocytes and hepatocytes (Karamanlidis et al., 2007; Karamitri et al., 2009; Wang et al., 2008 indicates the membrane intact mitochondria. R2 indicates the membrane detective mitochondrial. C, The protein abundance of Puma, Bak, Bax, and Bim in isolated mitochondria from E8.5 embryos. D, The protein abundance of tBid (cleaved), pBad (phosphorylated) in E8.5 embryos. Bar graphs for protein abundance were quantitative data from 3 independent experiments. *indicate significant difference compared with other groups. ND: non-diabetic dams; DM: diabetic dams; KO: CHOP knockout. * indicate significant difference (p < .05) compared with other groups.
immunoprecipitation reveals that C/EBPb binds to the cAMP response element of the PGC-1a promoter and positively regulates PGC-1a expression (Karamitri et al., 2009 ). To investigate the potential role of C/EBPb on the CHOP-suppressed PGC-1a expression, ectopic C/EBPb overexpression was applied. C/EBPb overexpression did not affect high glucose-increased CHOP expression, whereas it reversed high glucose-inhibited PGC-1a expression ( Figure 5A ). These findings were confirmed in tunicamycin treatment. Tunicamycin treatment increased CHOP expression and decreased PGC-1a expression (
Figure 5B siRNA under normal or high glucose conditions. Bar graphs for protein abundance were quantitative data from 3 independent experiments. E, The mRNA abundance of PGC-1a and CHOP in C17.2 cells transfected with or without CHOP expression vector under normal or high glucose conditions. F, The protein abundance of PGC-1a
and CHOP in C17.2 cells transfected with or without CHOP expression vector under normal or high glucose conditions. Bar graphs for protein abundance were quantitative data from 3 independent experiments. G, PGC-1a promoter activity analyzed by relative luciferase reporter activities in C17.2 cells. Experiments were repeated overexpression did not change the stimulatory effect of tunicamycin on CHOP expression ( Figure 5B ). Nevertheless, C/EBPb overexpression abolished tunicamycin-induced PGC-1a suppression ( Figure 5B ).
CHOP Inhibits C/EBPb DNA-Binding Activity by Forming CHOP-C/ EBPb Heterodimers Because C/EBPb overexpression did not affect CHOP expression, we hypothesized that high glucose-or maternal diabetes- 
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RelaƟve increased CHOP inhibits C/EBPb DNA-binding activity through forming the CHOP-C/EBPb complex. Co-immunoprecipitation showed that high glucose in vitro and maternal diabetes in vivo enhanced the association between CHOP and C/EBPb ( Figure 6A and B 6A,). To investigate whether increased CHOP blocks the binding ability of C/EBPb, C/EBPb consensus sites were identified in the PGC-1a promoter. There are 3 potential C/EBPb binding sites in the PGC-1a promoter at nucleotide positions À2409 to À2398, À765 to À754, and À16 to À5 ( Figure 6C ). ChIP assays were performed to evaluate C/EBPb binding to the PGC-1a promoter using primers spanning these 3 putative sites and demonstrated that C/EBPb only bound to the PGC-1a promoter at the position À765 to À754 (Figure 6D and E) . However, as a member of the C/EBP family, CHOP did not bind to the PGC-1a promoter ( Figure 6D and E). Both high glucose and maternal diabetes decreased the binding of C/EBPb to the promoter of PGC-1a, whereas CHOP siRNA knockdown in C17.2 cells under high glucose conditions and Chop gene deletion in embryos of diabetic dams restored the binding activity of C/EBPb to the PGC-1a promoter ( Figure 6D and E). Thus, elevated CHOP competitively interacts with C/EBPb in preventing its binding to the PGC-1a promoter leading to inhibition PGC-1a expression in diabetic embryopathy.
DISCUSSION
The purpose of this study was to investigate whether CHOP contributes to ER stress-induced neuroepithelial cell apoptosis in diabetic embryopathy, and to further identify the molecular mechanism underlying CHOP-mediated apoptosis in diabetic embryopathy. The results of the present study demonstrate that maternal diabetes-induced neuroepithelial cell apoptosis can be attributed to increased CHOP expression. Previous studies have shown that CHOP is involved in the mitochondriadependent apoptotic pathway by suppressing the expression of 2 major anti-apoptotic proteins Bcl-2 and Mcl-1, and upregulating the pro-apoptotic protein Bim (Iurlaro and MunozPinedo, 2016) . In addition, CHOP interacts with c-Jun and GCN5 to increase cell death receptor DR4 and DR5 expression leading to a widespread cleavage of caspases and cell death (Iurlaro and Munoz-Pinedo, 2016) . In the present study, CHOP is responsible for maternal diabetes-impaired mitochondrial function and caspase 3/8 cleavage. Thus, in diabetic embryopathy, ER stressinduced and CHOP-mediated neuroepithelial cell apoptosis occurs through the mitochondrial apoptotic pathway.
To elucidate how CHOP induces the mitochondrial dysfunction pathway of cell death, the present study focuses on the master regulator of mitochondrial biogenesis and respiration PGC-1a. C/EBPb is a positive regulator for PGC-1a, whereas CHOP antagonizes the transcriptional activity of C/EBPb (Chikka et al., 2013; Karamitri et al., 2009; Ron and Habener, 1992; Tang and Lane, 2000) . The current findings reveal that maternal diabetesor high glucose-increased CHOP reduces PGC-1a expression, and deletion or knocking down of CHOP restores PGC-1a expression. In contrast, C/EBPb overexpression reverses the effect of maternal diabetes or high glucose on PGC-1a expression. Previous studies suggest that both CHOP and C/EBPb can bind together to the C/EBP-binding site in the promoters of target genes (Chikka et al., 2013; Karamitri et al., 2009 ). However, CHOP cannot bind to the PGC-1a promoter directly in fat tumor cells (Karamitri et al., 2009 ). In fact, CHOP lacks the DNA-binding activity for the C/EBP-binding consensus sequence in promoter regions because of 2 proline residues in its DNA-binding domain, and a unique DNA sequence termed as the CHOPbinding site is required for CHOP to bind to a specific promoter (Ohoka et al., 2007; Tang and Lane, 2000) . The findings in this present study confirmed that CHOP could not directly bind to the PGC-1a promoter directly. Additionally, CHOP cannot form homodimers, but it inhibits the DNA binding activity of other C/ EBP proteins such as C/EBPb and exerts transcriptional regulatory activity through forming heterodimers with other C/EBP proteins (Ron and Habener, 1992) . In this study, the direct interaction between CHOP and C/EBPb is identified and enhanced by ER stress induced by high glucose. Chop gene deletion or knocking down CHOP restores high glucose-suppressed C/EBPb binding to the PGC-1a promoter. Thus, CHOP suppresses PGC-1a expression by inhibiting the DNA-binding ability of C/EBPb through forming CHOP-C/EBPb heterodimers, ultimately leading to mitochondrial dysfunction. The molecular mechanism underlying maternal diabetes or high glucose enhances the CHOP-C/EBPb heterodimer formation still remains to be elucidated. It is possible that high glucose dramatically induces CHOP expression leading to the increased formation of CHOP-C/EBPb heterodimers. In addition, modification of a transcription factor, such as phosphorylation, glycosylation and acetylation, may affect its DNA binding activity and function. Indeed, glycosylation of C/EBPb prevents its phosphorylation and DNA binding activity (Li et al., 2009) . Glycosylation of C/EBPb may enhance CHOP-C/EBPb heterodimers formation in inhibiting C/EBPb DNA transcription activity.
Previous studies have demonstrated that PGC-1a activates autophagy both in vivo and in vitro (Wang et al., 2017) , and PGC1a overexpression in the developing neuroepithelium restores maternal diabetes-suppressed autophagy and alleviates NTDs in diabetic pregnancy (Wang et al., 2017) . In the present study, we demonstrated that Chop gene deletion ameliorated maternal diabetes-induced NTD formation and CHOP is the negative regulator for PGC-1a expression at the transcriptional level. The previous study also reveals that miR-129-2 mediates the inhibitory effect of high glucose on PGC-1a expression (Wang et al., 2017) . Thus, maternal diabetes represses PGC-1a expression at both transcriptional and post-transcriptional levels.
Because PGC-1a is an autophagy activator (Wang et al., 2017) , CHOP may also contribute to maternal diabetes-induced neuroepithelial cell apoptosis and NTD formation through the autophagy pathway. ER stress-increased CHOP under maternal diabetic conditions suppresses PGC-1a expression, and, thus, PGC-1a-induced autophagy is inhibited and leads to accumulation of damaged mitochondria which causes mitochondrial dysfunction and the mitochondrial-dependent apoptosis in neuroepithelial cells. Recent studies have shown that CHOP has a dual role in both inducing apoptosis and limiting autophagy (Senft and Ronai, 2015) . As a result, CHOP may induce neuroepithelial cell apoptosis through inducing mitochondrial dysfunction and inhibiting autophagy.
Consistent with early studies showing that either Chop gene deletion or CHOP deficiency alleviates renal fibrosis in kidney diseases (Liu et al., 2016) , myocardial reperfusion injury and cardiac dysfunction induced by pressure overload (Miyazaki et al., 2011) , the present study reveals that Chop gene deletion inhibits diabetic embryopathy. These studies suggest that CHOP and its downstream signals may be potential therapeutic targets for ER stress-induced human pathogenesis. In summary, this study demonstrated that maternal diabetes-increased CHOP contributes to ER stress-induced neuroepithelial cell death through the mitochondrial-dependent apoptosis pathway.
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